Sung Ji Nam
Stock Analyst at Scotiabank
(2.79)
# 1,632
Out of 5,154 analysts
83
Total ratings
49.28%
Success rate
5.81%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $91.20 | -34.21% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $53.89 | +39.17% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $195.50 | +40.66% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $501.97 | +17.54% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $124.62 | +0.30% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $27.12 | +47.49% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $18.78 | +112.99% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $5.15 | +16.50% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.12 | +257.14% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.38 | +44.93% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $103.50 | -29.47% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $14.86 | -19.25% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $302.54 | +48.74% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $46.94 | +32.08% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $33.85 | +29.99% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $17.89 | +95.64% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $2.11 | +184.36% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.63 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $91.20
Upside: -34.21%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $53.89
Upside: +39.17%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $195.50
Upside: +40.66%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $501.97
Upside: +17.54%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $124.62
Upside: +0.30%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $27.12
Upside: +47.49%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $18.78
Upside: +112.99%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $5.15
Upside: +16.50%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.12
Upside: +257.14%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.38
Upside: +44.93%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $103.50
Upside: -29.47%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $14.86
Upside: -19.25%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $302.54
Upside: +48.74%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $46.94
Upside: +32.08%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $33.85
Upside: +29.99%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $17.89
Upside: +95.64%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $2.11
Upside: +184.36%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $14.63
Upside: -